Inogen, Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021; filed February 24, 2022. The filing is an annual report, and the supplied text does not provide a clear standalone fourth-quarter financial summary.
Business context
Inogen develops, manufactures and markets portable oxygen concentrators and related respiratory products. It sells through direct-to-consumer sales and rentals, as well as home medical equipment providers, distributors and resellers. The business is exposed to healthcare reimbursement policy, product demand, supply availability and international regulatory requirements.
Key financial metrics
| Metric | FY2021 | FY2020 |
|---|---|---|
| Total revenue | $358.0 million | $308.5 million |
| Sales revenue | $311.7 million | $280.2 million |
| Rental revenue | $46.3 million | $28.3 million |
| Gross profit / gross margin | $176.5 million / 49.3% | $138.2 million / 44.8% |
| Operating income (loss) | $9.2 million | $(12.0) million |
| Net income (loss) | $(6.3) million; $(0.28) per diluted share | $(5.8) million; $(0.27) per diluted share |
| Adjusted EBITDA (non-GAAP) | $29.5 million | $21.6 million |
| Cash from operating activities | $23.6 million | $37.0 million |
| Cash and cash equivalents; marketable securities | $235.5 million; $10.0 million | $212.0 million; $19.3 million |
| Working capital | $267.7 million | $249.0 million |
At year-end, total liabilities were $119.3 million, including operating lease and earnout liabilities; the balance sheet lists no borrowings or other debt. Operating cash flow declined year over year, while cash and cash equivalents increased. Capital spending and rental-asset purchases totaled approximately $24.1 million. Medicare reimbursement programs accounted for 10.6% of total revenue, and revenue from outside the United States was 22.2%.
Material changes versus FY2020
- Revenue rose 16.1%, driven by higher direct-to-consumer sales, international business-to-business sales and rentals. Rental revenue grew 63.5%; sales revenue grew 11.3%.
- System sales declined 1.7% to approximately 175,800 units. Domestic business-to-business sales fell 5.2%, with supply constraints limiting availability.
- Sales gross margin increased to 48.1% from 44.1%; rental gross margin increased to 57.4% from 52.1%. Overall gross margin improved to 49.3% from 44.8%.
- Operating results improved to $9.2 million of income from a $12.0 million operating loss, but net loss widened modestly to $6.3 million. A $14.4 million income tax expense, including a $17.4 million valuation allowance against deferred tax assets, was a major factor.
- Adjusted EBITDA increased to $29.5 million from $21.6 million. This non-GAAP measure excludes, among other items, stock-based compensation and changes in the New Aera earnout liability.
Outlook, risks and unusual items
- Supply constraints: Semiconductor shortages and higher component costs affected 2021 margins and sales. Manufacturing at the company’s U.S. sites and Czech contract manufacturer was temporarily suspended in January 2022 and restarted in early February. Management expected supply constraints, cost inflation and possible inability to meet all demand to continue during 2022.
- Reimbursement: Rental growth benefited from higher Medicare rates and temporary COVID-19-related administrative flexibility. Management flagged possible rate reductions after the public health emergency, resumed sequestration reductions, and uncertainty around future competitive bidding and implementation of revised oxygen coverage rules.
- Europe: Continued EU sales depend on certification under the Medical Device Regulation. The filing describes preparation of submissions and potential country-level exemptions; failure or delay could disrupt sales after applicable transition deadlines.
- Management outlook: No formal quantitative revenue or earnings guidance is provided. Management planned to grow rentals, improve sales productivity, expand prescriber sales and marketing, and develop products, while noting supply, hiring, COVID-19 and reimbursement uncertainties. The TAV product was expected to make a limited revenue contribution in its current configuration.
- Other notable items: The New Aera earnout liability was reduced by $11.6 million in fair value during 2021, lowering general and administrative expense; up to $31.4 million in earnout payments remained contingent. The $6.2 million CARES Act relief funding benefited 2020 results, not 2021. A securities class action was dismissed in 2021; related derivative cases were dismissed without prejudice. The company reported effective disclosure controls and internal control over financial reporting, and Deloitte issued unqualified audit opinions.
- Principal risks: Supplier concentration and production interruptions; Medicare and private-payor reimbursement changes; competition and customer concentration; product liability and regulatory compliance; international certification and currency exposure; and the ability to recruit and retain sales and technical staff.
Important facts for investors to verify
- Whether semiconductor supply, production capacity and component costs improved after the early-2022 shutdown, and the resulting effect on unit sales and gross margins.
- Whether the EU regulatory certifications were obtained on time and whether any sales were interrupted.
- How Medicare rates and coverage determinations changed after the COVID-19 public health emergency, including sequestration and competitive-bidding policy.
- Whether rental patient growth translates into durable revenue and cash generation, considering capped-rental obligations, reimbursement denials and servicing costs.
- The assumptions underlying the deferred-tax-asset valuation allowance and New Aera earnout valuation, as well as the company’s progress toward sustainable GAAP profitability.